Journal
EMBO JOURNAL
Volume 35, Issue 5, Pages 459-461Publisher
WILEY-BLACKWELL
DOI: 10.15252/embj.201593584
Keywords
-
Categories
Funding
- European Research Council (ERC) [670126] Funding Source: European Research Council (ERC)
- European Research Council [670126] Funding Source: Medline
Ask authors/readers for more resources
Treatment with BRAF kinase inhibitors leads to rapid resistance and tumor regression in BRAF V600E mutant melanoma patients. However, the underlying mechanism of the developed tumor resistance is not fully clear. In this issue of The EMBO Journal, Kim and colleagues show that melanoma cells acquire resistance to BRAF inhibitors by changing cell shape, modifying their cytoskeleton and, in turn, activating the YAP/TAZ mechanotransduction pathway (Kim et al, 2016).
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available